$Hims & Hers Health Inc.(HIMS)-To The Moon - Tiger Brokers Online Investing Community - To The Moon

$Hims & Hers Health Inc.(HIMS)$ Just sharing my opinion. The latest dip begun to look attractive. [Smile]

Hims & Hers Health (HIMS) stock has fallen to the $16 range primarily due to intense legal and regulatory pressure surrounding its compounded GLP-1 weight-loss products, compounded by a lawsuit from Novo Nordisk and fears of lost market share.

Here are the specific reasons for the decline:

Lawsuit and Regulatory Pressure: In early February 2026, Novo Nordisk filed a lawsuit against Hims & Hers to permanently ban the company from selling compounded versions of its drugs (such as Ozempic and Wegovy). This followed a direct warning from the FDA regarding "illegal copycat drugs".

Withdrawal of Copycat Product: Hims & Hers announced it would stop selling a specific compounded version of a weight-loss pill that closely mimicked Wegovy, bowing to pressure from federal regulators.

End of Shortage Status: The FDA previously indicated that shortages of semaglutide products (the active ingredient in Wegovy/Ozempic) have been resolved, limiting the legal grounds under which pharmacies can produce compounded alternatives.

Context for the Stock Performance:

Despite these, the company has shown strong year-over-year revenue growth. However, the regulatory noise, lawsuits, and the end of the "GLP-1 gravy train" have caused a major valuation pullback, with the stock losing approximately 50% of its value in early 2026 compared to its prior highs.

Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

447

12

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":533843156882712,"tweetId":"533843156882712","gmtCreate":1771354371159,"gmtModify":1771372992885,"author":{"id":4095252946433820,"idStr":"4095252946433820","authorId":4095252946433820,"authorIdStr":"4095252946433820","name":"Jason_LSE","avatar":"https://community-static.tradeup.com/news/3743bc1061440e3bac7c0e9716f3703a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":13,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.02.14","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}},"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.02.18","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"fanSize":103,"starInvestorFlag":false},"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","categoryId":"7cf744760f454845a1870a05ea4e151d","name":"Winning Trades","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":7516f9ef7e8042739b8597466da26fe7}&rnconfig={\"headerBarHidden\": true}","description":"Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.","image":"https://community-static.tradeup.com/news/14c89d9656aedb9a4698e7996c575947"}],"images":[{"img":"https://community-static.tradeup.com/news/9391b5720c1ca55043faf6bf6604dac3","width":"584","height":"1147"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/9391b5720c1ca55043faf6bf6604dac3","width":"584","height":"1147"}],"title":"","html":"<html><head></head><body><p><a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$ </a>Just sharing my&nbsp;opinion.&nbsp;The latest dip begun to look attractive.&nbsp;<span>[Smile]&nbsp;</span>&nbsp;</p>\n<p>Hims &amp; Hers Health (HIMS) stock has fallen to the $16 range primarily due to intense legal and regulatory pressure surrounding its compounded GLP-1 weight-loss products, compounded by a lawsuit from Novo Nordisk and fears of lost market share.</p>\n<p>Here are the specific reasons for the decline:</p>\n<p>Lawsuit and Regulatory Pressure: In early February 2026, Novo Nordisk filed a lawsuit against Hims &amp; Hers to permanently ban the company from selling compounded versions of its drugs (such as Ozempic and Wegovy). This followed a direct warning from the FDA regarding \"illegal copycat drugs\".</p>\n<p>Withdrawal of Copycat Product: Hims &amp; Hers announced it would stop selling a specific compounded version of a weight-loss pill that closely mimicked Wegovy, bowing to pressure from federal regulators.</p>\n<p>End of Shortage Status: The FDA previously indicated that shortages of semaglutide products (the active ingredient in Wegovy/Ozempic) have been resolved, limiting the legal grounds under which pharmacies can produce compounded alternatives.</p>\n<p>Context for the Stock Performance:</p>\n<p>Despite these, the company has shown strong year-over-year revenue growth. However, the regulatory noise, lawsuits, and the end of the \"GLP-1 gravy train\" have caused a major valuation pullback, with the stock losing approximately 50% of its value in early 2026 compared to its prior highs.&nbsp;</p><img src=\"https://community-static.tradeup.com/news/9391b5720c1ca55043faf6bf6604dac3\" tg-width=\"584\" tg-height=\"1147\"></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$ </a>Just sharing my&nbsp;opinion.&nbsp;The latest dip begun to look attractive.&nbsp;<span>[Smile]&nbsp;</span>&nbsp;</p>\n<p>Hims &amp; Hers Health (HIMS) stock has fallen to the $16 range primarily due to intense legal and regulatory pressure surrounding its compounded GLP-1 weight-loss products, compounded by a lawsuit from Novo Nordisk and fears of lost market share.</p>\n<p>Here are the specific reasons for the decline:</p>\n<p>Lawsuit and Regulatory Pressure: In early February 2026, Novo Nordisk filed a lawsuit against Hims &amp; Hers to permanently ban the company from selling compounded versions of its drugs (such as Ozempic and Wegovy). This followed a direct warning from the FDA regarding \"illegal copycat drugs\".</p>\n<p>Withdrawal of Copycat Product: Hims &amp; Hers announced it would stop selling a specific compounded version of a weight-loss pill that closely mimicked Wegovy, bowing to pressure from federal regulators.</p>\n<p>End of Shortage Status: The FDA previously indicated that shortages of semaglutide products (the active ingredient in Wegovy/Ozempic) have been resolved, limiting the legal grounds under which pharmacies can produce compounded alternatives.</p>\n<p>Context for the Stock Performance:</p>\n<p>Despite these, the company has shown strong year-over-year revenue growth. However, the regulatory noise, lawsuits, and the end of the \"GLP-1 gravy train\" have caused a major valuation pullback, with the stock losing approximately 50% of its value in early 2026 compared to its prior highs.&nbsp;</p><img src=\"https://community-static.tradeup.com/news/9391b5720c1ca55043faf6bf6604dac3\" tg-width=\"584\" tg-height=\"1147\"></body></html>","text":"$Hims & Hers Health Inc.(HIMS)$ Just sharing my opinion. The latest dip begun to look attractive. [Smile] Hims & Hers Health (HIMS) stock has fallen to the $16 range primarily due to intense legal and regulatory pressure surrounding its compounded GLP-1 weight-loss products, compounded by a lawsuit from Novo Nordisk and fears of lost market share. Here are the specific reasons for the decline: Lawsuit and Regulatory Pressure: In early February 2026, Novo Nordisk filed a lawsuit against Hims & Hers to permanently ban the company from selling compounded versions of its drugs (such as Ozempic and Wegovy). This followed a direct warning from the FDA regarding \"illegal copycat drugs\". Withdrawal of Copycat Product: Hims & Hers announced it would stop selling a specific compounded version of a weight-loss pill that closely mimicked Wegovy, bowing to pressure from federal regulators. End of Shortage Status: The FDA previously indicated that shortages of semaglutide products (the active ingredient in Wegovy/Ozempic) have been resolved, limiting the legal grounds under which pharmacies can produce compounded alternatives. Context for the Stock Performance: Despite these, the company has shown strong year-over-year revenue growth. However, the regulatory noise, lawsuits, and the end of the \"GLP-1 gravy train\" have caused a major valuation pullback, with the stock losing approximately 50% of its value in early 2026 compared to its prior highs.","highlighted":1,"essential":1,"paper":1,"likeSize":447,"commentSize":0,"repostSize":12,"favoriteSize":0,"link":"https://ttm.financial/post/533843156882712","repostId":0,"isVote":1,"tweetType":1,"viewCount":1257,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["HIMS"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":true,"length":1234,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/533843156882712"}